Replies to post #14707 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Budzar and MDA also release ongoing phase I trial data. Budzar is a hypocrite.

It's both right and salutary to release ongoing phase I trial data in PRs. The PRs avoid discriminatory dissemination of trial data which large institutions are excellent at obtaining. Just as DCVAX-L's treatment is not predisposed to certain genetic constituencies, so too, NWBO PR releases of open label ongoing phase I trial data provides information for all, not just the powerful and connected.

[Doktornolittle]

Barnstormer: "I believe MDA would have been happy to stay out of the dust up had it not been for the passionate attack against them as an institution by some NBWO stock holders that let passion and righteous indignation over ride common sense. As it was, MDA had respond to the criticism, again from an institutional aspect."

I understand what you are saying, but I would point out that their potential liability/tarnish was already removed three weeks earlier when Adam Feuerstein publicly quoted Dr. Subbiah has having said that MD Anderson would not be releasing any trial results until after the trial was completed, but that Northwest Biotherapeutics was free to do so now, if they so chose. This created a clear public record that MDA was not involved with the release; that Northwest was acting on it's own.

And that should have been the extent of MD Anderson's input. Given that they never looked at the patient reports, they are not in a position to say the data release was inappropriate. However unusual it is for ongoing phase 1 data to be meaningful, of course it could be, if the patient population is enough of a challenge, and the preliminary results are good enough.